Methotrexate for Injection USP

DECEMBER 01, 2005

Bedford Laboratories (Bedford, Ohio), a division of Ben Venue Laboratories Inc, recently added Methotrexate for Injection USP, 1 g, to its line of oncology products. Methotrexate for Injection USP is indicated for the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. The product is supplied in 4 singledose, preservative-free liquid presentations, containing 25 mg/mL of methotrexate sodium?50 mg in 2 mL, 100 mg in 4 mL, 200 mg in 8 mL, 250 mg in 10 mL?and in a 1- g single-dose, preservative-free lyophilized powder. For more information, visit www.bedfordlabs.com, or call 800-521-5169.



SHARE THIS SHARE THIS
0
 

AF Risk Increases with More Pregnancies

One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.